Cure8 research brief
The review highlights marine polysaccharides as multi-target agents that could modulate inflammation, the microbiome, and the gut barrier—processes central to ulcerative colitis—and points to possible roles as functional foods or adjunctive therapies pending clinical validation.
Researchers in natural products and microbiome therapeutics; clinicians exploring adjunctive or dietary approaches for UC; adult patients interested in emerging preclinical therapies.
This is a systematic review-style article (abstract level provided) summarizing sources, structures, and mechanisms of polysaccharides from seaweeds, marine animals, and microorganisms in models of ulcerative colitis.
The authors link physicochemical features (molecular weight, sulfation, monosaccharide composition) to biological effects and describe multiple proposed mechanisms: modulation of gut microbiota and short-chain fatty acids, suppression of inflammatory pathways (NF-κB, MAPK, NLRP3), regulation of immune cells (dendritic cells, Th1/Th17), reduction of oxidative stress (Nrf2/HO-1), and strengthening of intestinal barrier proteins and mucins.
The review emphasizes that most data come from preclinical studies; safety characterization and clinical trials are limited. Key translational challenges noted include structural heterogeneity, batch consistency, bioavailability, and the need for standardized characterization and clinical evaluation.
Summary is based on the article abstract (structured content depth: abstract). Most evidence described is preclinical; clinical validation and standardized product characterization are currently limited.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China, award 82360809; National Natural Science Foundation of China, award 82304828; award 82360809; award 82304828; Science and Technology Projects of Guizhou Province, award QKHJC-MS [2026]912; Future “Science and Technology Elite” Project, award ZYSE-2025-04; Future “Science and Technology Elite” Project, award ZYSE-2022-01
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
